Table 1.
Prevalence rates of SVT among MPNs, prevalence rates of MPN among non-cirrhotic, non-local malignancy-related SVTs.
| MPN | Prevalence of SVT | References |
|---|---|---|
| PV | 5.5–10.0% | 14/140 with SVT (10%) [10] |
| 13/235 (5.5%) with BCS and PMVT [11] | ||
| ET | 4.0–13.0% | 3/23 (13%) with SVT [10] |
| 19/460 (4%) with SVT [12] | ||
| 24/259 (9.2%) with BCS and PMVT [11] | ||
| PMF | 0.6–1.0% | 1/106 (1%) with SVT [10] |
| 4/707 (0.6%) with SVT [13] | ||
| SVT | Prevalence of MPN | References |
| PVT | 31.5% | 188/615 (31.5%) with MPN [7] |
| 27.5% PV | ||
| 26.2% ET | ||
| 12.8% MF | ||
| 17.7% MPN-U | ||
| 24.0% solitary JAK2V617F+ | ||
| BCS | 40.9% | 180/440 (40.9%) with MPN [7] |
| 52.9% PV | ||
| 24.6% ET | ||
| 6.7% MF | ||
| 17.0% MPN-U | ||
| 6.5% solitary JAK2V617F+ |
BCS, Budd–Chiari syndrome; ET, essential thrombocythemia; MF, myelofibrosis; MPN, myeloproliferative neoplasm; MPN-U, MPN-unclassifiable; PMF, primary myelofibrosis; PMVT, portal mesenteric vein thrombosis; PV, polycythemia vera; SVT, splanchnic vein thrombosis.